I'm mapping out the timeline for notifications. Discovery happens Wednesday at 10 a.m., then I need to calculate when the ethics board and regulator deadlines fall. The ethics board gets five business days from discovery (Thursday through the following Wednesday), while the regulator has seven calendar days, which also lands on the following Wednesday.

However, there's ambiguity in how to count the days — whether discovery day itself counts as day zero or day one. To be safe, I should advise filing the board report by Friday and the regulator by Monday to avoid any interpretation issues. I also need to verify whether each site has faster local reporting requirements in their approved plans, since the rule requires compliance with any site-specific timelines, and I shouldn't assume they don't exist without checking.

One more critical point: the 62 unknown cases must be treated as presumptively affected for intervention holds. The rule doesn't allow me to assume all or none are in scope, so I need to take a precautionary approach and hold nonurgent interventions until I can confirm the status of each case individually.

For the immediate response, I'm looking at a two-hour window starting Wednesday to implement standing orders. The key actions are stopping new enrollment study-wide under version 4.2, and halting all nonurgent interventions for both the confirmed 4.2 subjects and the unknown-version subjects — that's 12 implants total on hold. Since version control is broken and I can't verify which form sites are actually using, I need to pause all new enrollment study-wide until version control is restored and the correct form is approved, then lift the pause site-by-site as documentation is confirmed.

Next, I'm rejecting the investigator's proposal to implant then send a follow-up email, since that violates multiple rules and post hoc disclosure can't retroactively fix a pre-intervention violation. I'm also rejecting any PDF replacement attempt as spoliation under rule 8, which means issuing a litigation hold, locking database write access, and restoring from backups if any replacement already happened. For ongoing care, routine safety visits must continue under rule 3, but I need to separate clinical safety assessment from research-only procedures — those research elements require re-consent and new risk disclosure before proceeding.

For the nerve-weakness event already reported through safety channels, I'm re-reporting it in the context of consent noncompliance, contacting the subject within 24 hours with risk information and a neurological evaluation offer, and documenting everything without backdating. I'll assess whether this qualifies as an unanticipated problem or adverse device effect requiring separate reporting, and offer the subject re-consent for continued data use and follow-up. Now I'm drafting a factual chronology and preparing the board report.

For the emergency Thursday meeting, I need to compile the submission package with root cause analysis, version comparisons, affected subject counts, the hold plan, corrected consent forms, re-consent scripts, notification letters for completed subjects, the data-use decision, safety visit plan, and scope verification timeline. The board will need to approve the corrected consent, the re-consent process, notification letters, decide on continued data use, approve conditions for resuming enrollment by site, and determine next steps — all with a regulator report due Friday or Monday and a hard deadline the following Wednesday.

For re-consent, subjects who haven't been implanted yet need to sign the corrected form in person with a fresh date and new signature, documenting the version and time; anyone declining gets withdrawn from the intervention with clinical alternatives offered outside the study. For the eight subjects with unknown versions, I'll verify by medical record, but regardless, all twelve get re-consented on the corrected form — that's the simplest and most defensible approach. Implants only resume after board approval, confirmed version determination, and completed re-consent.

For those already implanted, they receive written notice with a documented conversation covering the risk information, the omission, the 3% incidence, symptoms, what to do, contact details, and follow-up plans, plus their choice about continued data use and follow-up; I'll obtain new consent or authorization for continued data use per board direction and document any refusals without backdating.

I'm not destroying any data — instead, I'm flagging the 4.2-derived data with metadata tags, continuing safety collection, and letting the board decide on use while honoring withdrawal requests for future data. For documentation, I'm maintaining a consent version control log with effective dates and distribution records, keeping signed originals at sites with PDF upload timestamps and audit trail metadata, plus EDC audit trails and document management system records.

I need to track version logs showing the root cause of the 4.2 conversion error, creation and distribution timestamps, IRB approval letters per version, site printing records, screening and enrollment logs, delegation logs, monitoring reports, email transmittals, and subject-level attestation from each PI naming the version used with source documents verified independently by monitors on-site with full discrepancy resolution — all uploaded within 48 to 72 hours.

For privilege, I'm separating operational fact-finding by QA and clinical teams, which stays non-privileged and reportable, from privileged legal analysis under counsel, labeling each properly and not routing the factual chronology through counsel to shield it, and I won't claim privilege over the consent records themselves.

I need to instruct staff that privilege doesn't excuse candor, avoid mixed memos, and follow the 72-hour and 7-day timelines. If the CSO requests anything, I refuse and escalate, noting the regulatory consequence of falsification, issuing written direction, verifying no changes were made, and considering access restrictions and database audit logs — if changes did occur, I disclose to the board and regulator.

Beyond that, I'm coordinating a sponsor-wide communication to all sites within hours with a written stop-enrollment notice and confirmation of receipt, monitoring deployment and training, and checking whether other forms or translations are affected, like version 4.2 in other languages or other documents using the same template. For the 20 confirmed subjects on versions 4.1 or 4.3, they can continue if the version is confirmed and contains the risk, though their upcoming interventions may need review.